A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors
Related Experiment Videos
1Rehabilitationsklinik Glotterbad, Blottertal, West Germany.
Insights
Celiprolol significantly reduced blood pressure and heart rate in hypertensive patients. This medication also improved lipid profiles and unexpectedly lowered fibrinogen levels, suggesting potential benefits against thrombosis.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a prevalent cardiovascular condition associated with increased blood viscosity and risk of complications.
- Celiprolol is a beta-blocker with potential vasodilatory properties.
Purpose of the Study:
- To evaluate the efficacy and safety of once-daily celiprolol in patients with essential hypertension.
- To assess the impact of celiprolol on blood pressure, heart rate, lipid profile, and fibrinogen levels.
Main Methods:
- A 12-month open-label study involving 12 patients with essential hypertension.
- Patients received a daily dose of 200 mg of celiprolol.
- Measurements included blood pressure, heart rate, serum lipids, and fibrinogen levels.
Main Results:
- Celiprolol significantly reduced mean supine blood pressure (162/102 to 134/84 mm Hg) and standing blood pressure (155/101 to 134/88 mm Hg).
- Heart rate, serum cholesterol, low-density lipoprotein, triglycerides, and fibrinogen levels were significantly decreased.
- No adverse drug effects were reported.
Conclusions:
- Once-daily celiprolol (200 mg) is effective in lowering blood pressure and heart rate in patients with essential hypertension.
- Celiprolol demonstrates favorable effects on lipid profiles and significantly reduces fibrinogen levels.
- The reduction in fibrinogen may mitigate blood viscosity and potentially decrease hypertensive complications like thrombosis.
Abstract:
In a 12-month study of 12 patients with essential hypertension treated with once-daily celiprolol, 200 mg, mean supine blood pressure was reduced from 162/102 to 134/84 mm Hg (p less than 0.005)and standing pressures from 155/101 to 134/88 mm Hg (p less than 0.05). Similarly, heart rate fell from 83 to 71 beats/min in the supine position and from 90 to 79 beats/min in the standing position. Serum cholesterol level also fell from 5.35 to 4.78 mmol/L (p less than 0.01) and was accompanied by a nonsignificant loss of body weight. Lipid electrophoresis showed a nonsignificant increase in the high-density lipid fraction, from 1.2 to 1.7 mmol/L, and a significant decrease in the low-density lipid fraction, from 3.4 to 2.7 mmol/L (p less than 0.01). Serum triglyceride levels also decreased from 1.85 to 1.37 mmol/L (p less than 0.02), and low-density lipid-high-density lipid ratio fell from 3.29 to 2.03 (p less than 0.02). There was an unexpected reduction in serum fibrinogen levels, from 288 to 253 mg/dl (p less than 0.01). Aside from a slight reduction in the fasting blood glucose, there were no other significant changes in the urine or blood parameters, and no adverse drug effects occurred. It is likely that celiprolol's effect in reducing fibrinogen levels may minimize the increase in blood viscosity associated with the hypertensive state, whereas its effects on fibrinogen may herald a reduction in hypertensive complications such as thrombosis or retinal "cotton wool exudates." This warrants further investigation."